ProMIS Neurosciences EBITDA vs. Cash And Equivalents
PMN Stock | USD 1.03 0.07 7.29% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -17.8 M | Current Value -16.9 M | Quarterly Volatility 8.2 M |
For ProMIS Neurosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ProMIS Neurosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ProMIS Neurosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ProMIS Neurosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ProMIS Neurosciences over time as well as its relative position and ranking within its peers.
ProMIS |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.04 | Revenue Per Share 0.001 | Return On Assets (4.81) | Return On Equity (10.99) |
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ProMIS Neurosciences Cash And Equivalents vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ProMIS Neurosciences's current stock value. Our valuation model uses many indicators to compare ProMIS Neurosciences value to that of its competitors to determine the firm's financial worth. ProMIS Neurosciences is regarded second in ebitda category among its peers. It is rated below average in cash and equivalents category among its peers . ProMIS Neurosciences reported last year EBITDA of (17.81 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ProMIS Neurosciences' earnings, one of the primary drivers of an investment's value.ProMIS Cash And Equivalents vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
ProMIS Neurosciences |
| = | (17.81 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
ProMIS Neurosciences |
| = | 8.95 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
ProMIS Cash And Equivalents Comparison
ProMIS Neurosciences is currently under evaluation in cash and equivalents category among its peers.
ProMIS Neurosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ProMIS Neurosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ProMIS Neurosciences will eventually generate negative long term returns. The profitability progress is the general direction of ProMIS Neurosciences' change in net profit over the period of time. It can combine multiple indicators of ProMIS Neurosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last Reported | Projected for Next Year | ||
Accumulated Other Comprehensive Income | -491.8 K | -467.2 K | |
Operating Income | -18.9 M | -18 M | |
Income Before Tax | -17.5 M | -16.6 M | |
Total Other Income Expense Net | 1.4 M | 1.4 M | |
Net Loss | -17.5 M | -16.6 M | |
Income Tax Expense | -167.9 K | -159.5 K | |
Net Interest Income | -124.6 K | -130.8 K | |
Net Loss | -16.9 M | -16.1 M | |
Net Loss | -16.3 M | -17.1 M | |
Interest Income | 5.4 K | 5.7 K | |
Change To Netincome | -4.2 M | -4 M | |
Net Loss | (1.42) | (1.50) | |
Income Quality | 0.82 | 0.66 | |
Net Income Per E B T | 0.81 | 1.01 |
ProMIS Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ProMIS Neurosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ProMIS Neurosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ProMIS Neurosciences' important profitability drivers and their relationship over time.
Use ProMIS Neurosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProMIS Neurosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProMIS Neurosciences will appreciate offsetting losses from the drop in the long position's value.ProMIS Neurosciences Pair Trading
ProMIS Neurosciences Pair Trading Analysis
The ability to find closely correlated positions to ProMIS Neurosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProMIS Neurosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProMIS Neurosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProMIS Neurosciences to buy it.
The correlation of ProMIS Neurosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProMIS Neurosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProMIS Neurosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProMIS Neurosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ProMIS Neurosciences position
In addition to having ProMIS Neurosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Recreation Thematic Idea Now
Recreation
Companies involved in production and services of recreational goods, foods, and accessories. The Recreation theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recreation Theme or any other thematic opportunities.
View All Next | Launch |
Check out Your Equity Center. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
To fully project ProMIS Neurosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ProMIS Neurosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ProMIS Neurosciences' income statement, its balance sheet, and the statement of cash flows.